Rockland Trust Co. Boosts Stock Position in Zoetis Inc. $ZTS

Rockland Trust Co. increased its holdings in Zoetis Inc. (NYSE:ZTS) by 2,055.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 148,557 shares of the company’s stock after purchasing an additional 141,664 shares during the period. Rockland Trust Co.’s holdings in Zoetis were worth $18,691,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC lifted its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the 3rd quarter worth about $31,000. Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $32,000. Finally, Financial Consulate Inc. purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $118.02 on Wednesday. The stock has a market cap of $49.82 billion, a PE ratio of 19.60, a P/E/G ratio of 1.78 and a beta of 0.95. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23. The company has a 50-day moving average price of $123.12 and a 200 day moving average price of $128.57. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Morgan Stanley set a $160.00 target price on Zoetis in a report on Thursday, December 18th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.